Clinical Trials Browser

NETWORK × daratumumab × Other hematologic neoplasm × Clear all

NCT05289687 2026-03-02

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma